ライフサイエンスコーパス: cynomolgus monkey

1 IIb, but show higher levels of FcgammaRII in cynomolgus monkey.

2 gG1 antibody to oxidized LDL (anti-oxLDL) in cynomolgus monkey.

3 n promising oral bioavailability in rats and cynomolgus monkey.

4 em closely homologous to that of humans, the cynomolgus monkey.

5 s high oral bioavailability in rat, dog, and cynomolgus monkey.

6 inding, and radiation dosimetry in a healthy cynomolgus monkey.

7 A PET study was performed on a cynomolgus monkey.

8 erated and confirmed to be cross-reactive to cynomolgus monkey.

9 netic/pharmacodynamic study was conducted in cynomolgus monkeys.

10 hippocampal IRS-1pSer and JNK activation in cynomolgus monkeys.

11 d both blood and bone marrow plasma cells in cynomolgus monkeys.

12 tic cleavage of FGF21 identified in mice and cynomolgus monkeys.

13 ghtly higher than typical IgG1 antibodies in cynomolgus monkeys.

14 e, and selectively reduce LDL-cholesterol in cynomolgus monkeys.

15 labeled material) to two male and two female cynomolgus monkeys.

16 us-sensitive, CD155 transgenic (tg) mice and cynomolgus monkeys.

17 e, after accounting for total volume, in the cynomolgus monkeys.

18 f total volume were determined in rhesus and cynomolgus monkeys.

19 heavy drinking within the inferior olive of cynomolgus monkeys.

20 ogenitor, CAT6001, in a single-dose study in cynomolgus monkeys.

21 rior cingulate cortex (ACC; Area 24) of male cynomolgus monkeys.

22 f PMNs from the bone marrow of both mice and cynomolgus monkeys.

23 nd pharmacokinetic analysis was performed in cynomolgus monkeys.

24 e different serum pools from male and female cynomolgus monkeys.

25 surgically menopausal young and middle-aged cynomolgus monkeys.

26 properties of 12p were assessed in rats and Cynomolgus monkeys.

27 tive primer and probe sets ever reported for cynomolgus monkeys.

28 one marrow transplant recipients of same sex cynomolgus monkeys.

29 g agent and evaluated as PET radioligands in cynomolgus monkeys.

30 d chimerism and renal allograft tolerance in cynomolgus monkeys.

31 mg/kg of LY2886721, a BACE1 inhibitor, in 2 cynomolgus monkeys.

32 s, and DST effectively prevents rejection in cynomolgus monkeys.

33 ian parvovirus (SPV) was first isolated from cynomolgus monkeys.

34 OP) changes in conscious ocular hypertensive cynomolgus monkeys.

35 < 0.001) lowered IOP in ocular hypertensive cynomolgus monkeys.

36 the corresponding biological consequences in cynomolgus monkeys.

37 reaction-mismatched, ABO blood group-matched cynomolgus monkeys.

38 fusion) was performed in one eye each of two cynomolgus monkeys.

39 oxyalaninyl phosphoramidate was evaluated in Cynomolgus monkeys.

40 travitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys.

41 rials of (225)Ac; there are no CD33 sites in cynomolgus monkeys.

42 efrontal and parietal cortex of adult female cynomolgus monkeys.

43 atured good oral bioavailability in mice and cynomolgus monkeys.

44 in vivo by administration of LymphoStat-B to cynomolgus monkeys.

45 mouse model, L(EV) was also tested in three cynomolgus monkeys.

46 fas ligand in blood samples from rhesus and cynomolgus monkeys.

47 f ACAT activity, was significantly higher in cynomolgus monkeys.

48 ntrathecal administration of rituximab using cynomolgus monkeys.

49 b/CD18 prevents progression of AKI to CKD in cynomolgus monkeys.

50 n of B cells and bone marrow plasma cells in cynomolgus monkeys.

51 ow background after intravenous injection in cynomolgus monkeys.

52 n stimulated gene (ISG) response in mice and cynomolgus monkeys.

53 bies virus-based EBOV vaccine, in rhesus and cynomolgus monkeys.

54 poor pharmacokinetic profile in both rat and cynomolgus monkeys.

55 to identify recently derived retrocopies in cynomolgus monkeys.

56 increased circulating intact FGF21 levels in cynomolgus monkeys.

57 retrocopies, all of which are polymorphic in cynomolgus monkeys.

58 ing strength of cocaine in group-housed male cynomolgus monkeys.

59 erapeutic target for autoimmune diseases, in cynomolgus monkeys.

60 d reduces fever after sublethal challenge in cynomolgus monkeys.

61 administration to lipopolysaccharide-treated cynomolgus monkeys.

62 electrocardiogram parameters in telemetrized cynomolgus monkeys.

63 al mice, mice transgenic for human FcRn, and cynomolgus monkeys.

64 inding protein 2 (MECP2), in both rhesus and cynomolgus monkeys.

65 r cell-mediated killing assay and in vivo in cynomolgus monkeys.

66 tal, 10 PET measurements were conducted on 5 cynomolgus monkeys.

67 I and demonstrated to modulate serum iron in cynomolgus monkeys.

68 on in livers of mice, rats, and dogs but not cynomolgus monkeys.

69 optic nerve margin in the right eyes of four cynomolgus monkeys.

70 One cynomolgus monkey (4.5 kg, intravenous ketamine/xylazine

71 e target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol

72 l genes across a broad range of tissues from cynomolgus monkey, a non-human primate model.

73 ant 3-fold increase of ACAT2 protein mass in cynomolgus monkeys, a much greater increase than was fou

74 In cynomolgus monkeys, a single injection of mAb1 reduces s

75 diet periods, liver biopsies were taken from cynomolgus monkeys, a species highly responsive to dieta

76 s, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACT

77 Cynomolgus monkeys administered ISIS 416858 (4, 8, 12, a

78 In cynomolgus monkeys, administration of LymphoStat-B resul

79 n and thrombus detection was investigated in cynomolgus monkeys after insertion of a roughened cathet

80 ifferentiated from the wild-type antibody in cynomolgus monkeys after intravenous administration.

81 n addition, R-13bhad good plasma exposure in cynomolgus monkeys after oral administration, with a C(m

82 nist-induced ex vivo platelet aggregation in cynomolgus monkeys after oral administration.

83 nduced ex-vivo platelet aggregation assay in cynomolgus monkeys after oral administration; this activ

84 accine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge.

85 lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (

86 264RAD cross-reacts with human, mouse and cynomolgus monkey alphavbeta6, and inhibits binding to a

87 nt anterograde and retrograde tracers in the cynomolgus monkey and found that all PMC areas are inter

88 in a 10-fold increase in its binding to both cynomolgus monkey and human FcRn at pH 6.0.

89 ed (>100-fold) stability over 1 or 5, with a cynomolgus monkey and human in vitro plasma half-life of

90 omolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',

91 flammatory cytokine induction pathway in the cynomolgus monkey and humans, but not observed systemica

92 and intravenous administration of NgR1-Fc to cynomolgus monkey and to rat are without evident toxicit

93 to 10,000-fold for CYP1A1 in vivo in rat and cynomolgus monkey and up to 45-fold for CYP1A1 and CYP1A

94 f NiV (Malaysia, Bangladesh) was assessed in cynomolgus monkeys and compared with henipavirus-infecte

95 r experience with severe sepsis in two young cynomolgus monkeys and five pigs that were subjected to

96 ormed 305 ovarian stimulations in 128 female cynomolgus monkeys and found that ovarian stimulation ca

97 gulation of the AOX promoter by PPARalpha in cynomolgus monkeys and humans and suggest that this mode

98 of (11)C-Lu AE92686 in the striatum of both cynomolgus monkeys and humans were evaluated by the simp

99 or PDE10A-expressing regions in the brain of cynomolgus monkeys and humans.

100 6 was evaluated as a PET tracer candidate in cynomolgus monkeys and in humans.

101 TT30 selectively inhibits CAP in cynomolgus monkeys and is bioavailable after subcutaneou

102 anslate to a pharmacokinetic benefit in both cynomolgus monkeys and mice when constructed on a differ

103 ed the same strategy, with modifications, to cynomolgus monkeys and most recently to renal transplant

104 erapy functionality of SiGdNP were tested in cynomolgus monkeys and pancreatic tumor-bearing mice mod

105 ound 6 had minimal effect on HDL-C levels in cynomolgus monkeys and showed human cadaver skin permeab

106 ntion of acute kidney allograft rejection in cynomolgus monkeys and synergizes with cyclosporine and/

107 ibose (ADPR) and ADP in colonic muscles from cynomolgus monkeys and wild-type (CD38(+/+)) and CD38(-/

108 the pharmacokinetic study of a mAb dosed in cynomolgus monkey, and the results were compared with th

109 olving NK cells, mediate XmAb5574 potency in cynomolgus monkeys, and that enhancing these mechanisms

110 PMNs to LukGH was similar between humans and cynomolgus monkeys, and was greater than that of rabbits

111 ) within the 2.3 kb proximal promoter of the cynomolgus monkey AOX gene.

112 This study indicates that cynomolgus monkeys are capable of metabolizing TAM to ge

113 In cynomolgus monkeys, ARGX-117 dose-dependently reduces fr

114 We have chosen the cynomolgus monkey as a model that is modestly responsive

115 bust and sustained anticoagulant activity in cynomolgus monkeys as assessed by activated partial thro

116 nge in resistance significantly increased in cynomolgus monkeys as total volume perfused increased (0

117 d higher titers of toxin-neutralizing Abs in cynomolgus monkeys at 2 wk compared with animals immuniz

118 8H9(dsFv)-PE38 was given to two cynomolgus monkeys at doses of 0.1 and 0.2 mg/kg i.v. QO

119 and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1).

120 When administered to cynomolgus monkeys at doses of 3 and 9 mg siRNA/kg, the

121 d 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical proper

122 BAFF-mediated survival and proliferation of cynomolgus monkey B cells.

123 kGH was administered to mice, rabbits, and a cynomolgus monkey by subcutaneous or intradermal injecti

124 tional to Delta n(RNFL)) was measured in two cynomolgus monkeys by enhanced polarization-sensitive op

125 MAb was administered to cynomolgus monkeys by intravenous and subcutaneous route

126 ribution of (125)I-AMG 386 was determined in cynomolgus monkeys by whole-body autoradiography and rad

127 Cynomolgus monkeys can be rendered memory phenotype enri

128 s compound 167 (CMPD 167), in an established cynomolgus monkey cardiac allograft model.

129 on of 1 mg/kg of body weight fully protected cynomolgus monkeys challenged with aerosolized anthrax s

130 barrier in archival formalin-fixed lungs of cynomolgus monkeys challenged with the fully virulent B.

131 ddition, we investigated the left MD in four cynomolgus monkeys chronically exposed to haloperidol an

132 Here, we analyzed cynomolgus monkey (CM) iPSC-derived midbrain dopamine ne

133 Each of six pairs of cynomolgus monkeys (CM) with streptozotocin-induced diab

134 d chimerism and renal allograft tolerance in cynomolgus monkeys, cyclophosphamide (CP) and total body

135 ements were performed on ex vivo lenses from cynomolgus monkeys (cyno: n = 120; age, 2.7-14.3 years),

136 cine and human therapeutic Ab development in cynomolgus monkeys (cynos) are influenced by immune resp

137 ic (PK) behavior of monoclonal antibodies in cynomolgus monkeys (cynos) is generally translatable to

138 in whole blood isolated from untransplanted cynomolgus monkeys (cynos), in vivo in blood from untran

139 inally, we validated these rodent studies in cynomolgus monkeys, demonstrating that a single 10-Gy do

140 way-derived cells from Ascaris suum-allergic cynomolgus monkeys did not produce appreciable TNF-alpha

141 mouse models of human lymphoma and in normal cynomolgus monkeys disclosed that low doses of veltuzuma

142 In cynomolgus monkeys, DNA vaccines containing the CMV enha

143 ng data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucag

144 alyzed 15 pairs of pregnant and non-pregnant cynomolgus monkeys, each pair of which received embryos

145 its a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice.

146 lture system that enabled the development of cynomolgus monkey embryos in vitro for up to 20 days.

147 o three target sites across 11 genes/loci in cynomolgus monkey embryos using CRISPR-based cytidine- a

148 DX-2930 injected subcutaneously into cynomolgus monkeys exhibited a long half-life (t(1/2) ap

149 Postmortem cynomolgus monkey eyes (n = 14; age range, 3.0-11.5 year

150 ic nerve head (ONH) and overlying vessels in cynomolgus monkey eyes were imaged with a fundus camera

151 in cultured anterior segments of rhesus and cynomolgus monkey eyes.

152 lecules and their SEFL variants to human and cynomolgus monkey FcgammaRs were evaluated using flow cy

153 tely 40-fold increase in binding affinity to cynomolgus monkey FcRn (C-FcRn) at pH 6.0, with maintena

154 esteryl ester concentrations were highest in cynomolgus monkeys fed cholesterol, despite the fact tha

155 ered CSF and cortex Abeta40 in both rats and cynomolgus monkeys following a single oral dose.

156 t tetravalent formulations were evaluated in cynomolgus monkeys following a single-dose subcutaneous

157 everal cases of symptomatic SPV infection in cynomolgus monkeys following heart transplantation.

158 platelet aggregation in an ex vivo model in cynomolgus monkeys following oral administration.

159 ng and cross-species comparisons with mouse, cynomolgus monkey gastrulae, and post-implantation human

160 compounds from each series in rat, dog, and cynomolgus monkey has led to the identification of 22 (C

161 ults for human IgG2 and IgG4 obtained in the cynomolgus monkey have to be cautiously interpreted, whe

162 Cynomolgus monkey heterotopic cardiac allograft recipien

163 ld prolonged half-life in mice, rabbits, and cynomolgus monkeys; however, the prolongation was less p

164 nd effector functions, whereas, in contrast, cynomolgus monkey IgG2 and IgG4 display strong effector

165 dies were assessed in a variety of human and cynomolgus monkey in vitro assays.

166 of B cells prior to heart transplantation in cynomolgus monkeys, in addition to conventional posttran

167 odels required dosing every 48 h, studies in cynomolgus monkeys indicate that less frequent dosing ma

168 -MS/MS assay for quantification of human and cynomolgus monkey interleukin 21 (IL-21) was developed,

169 c profile comparison of 8c and 12j in normal cynomolgus monkeys is discussed.

170 The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in

171 est that depressive behavior in adult female cynomolgus monkeys is similar to that observed in humans

172 in derivative rapamycin derivative (RAD), in cynomolgus monkey kidney allotransplantation.

173 A single administration of 27C3 to cynomolgus monkeys led to a rapid increase of plasma LCA

174 The cynomolgus monkey lens retains a significant fraction of

175 arried out metabolic stability studies using cynomolgus monkey liver and intestinal S9 fractions.

176 ve state in a non-human primate species, the cynomolgus monkey (Macaca fascicularis), in a realistic

177 were validated in DSM-denuded bladder of the cynomolgus monkey (Macaca fascicularis).

178 ntia tsutsugamushi (Kp r56) was evaluated in cynomolgus monkeys (Macaca fascicularis) for immunogenic

179 Data were collected from three awake cynomolgus monkeys (Macaca fascicularis) prepared for ch

180 injections in the lateral divisions of MD in cynomolgus monkeys (Macaca fascicularis) to assess the r

181 Cynomolgus monkeys (Macaca fascicularis) were immunized

182 SEARCH DESIGN AND At baseline, 32 male adult cynomolgus monkeys (Macaca fascicularis) were randomized

183 isms of spread, we infected groups of 5 or 6 cynomolgus monkeys (Macaca fascicularis) with either a w

184 injected into the mammillary bodies of five cynomolgus monkeys (Macaca fascicularis).

185 erograde and retrograde tracer injections in cynomolgus monkeys (Macaca fascicularis).

186 is study examined the connections of MITN in cynomolgus monkeys (Macaca fascicularis).

187 uences bone mass in soy-naive, premenopausal cynomolgus monkeys (Macaca fascicularis).

188 ropic Mycoplasma sp. in a research colony of cynomolgus monkeys (Macaca fascicularis).

189 CR in cynomolgus monkeys may alter insulin signaling in vivo b

190 1/2) and the lack of target cell antigens in cynomolgus monkeys may increase toxicity compared with h

191 A cynomolgus monkey model based on intravenous infusion of

192 t/CRISPR-associated nuclease 9 to generate a cynomolgus monkey model by disrupting SHANK3 at exons 6

193 In an acute cynomolgus monkey model of interleukin 6 (IL-6)-induced

194 el of fatal tuberculosis and the established cynomolgus monkey model to design an immuno-chemotherape

195 evaluated Mtb72F formulated in AS02A in the cynomolgus monkey model.

196 aft SCID mouse model and depletes B cells in cynomolgus monkeys more efficiently.

197 ge average: 41 +/- 17 years; range: 6-7) and cynomolgus monkey (n = 19; age average: 7.7 +/- 1.8 year

198 Cynomolgus monkey (n = 48; age: 3.8-11 years), rhesus mo

199 receptor availability was assessed in female cynomolgus monkeys (n = 16) with positron emission tomog

200 was IC-injected into rats (n = 72 eyes) and cynomolgus monkeys (n = 3).

201 In an in vivo model, cynomolgus monkeys (n = 6, each serving as its own contr

202 Normotensive cynomolgus monkeys (n = 8) were treated topically once d

203 Cynomolgus monkeys (n=28) were fed an atherogenic diet f

204 In a group of cocaine-experienced male cynomolgus monkeys (N=4), THC SA was examined under a se

205 istered to healthy mice by oral gavage or to cynomolgus monkeys (nonhuman primates) by colonic spray

206 the utility of preclinical species, rats and cynomolgus monkeys [nonhuman primates (NHPs)], to predic

207 One live delivery of a female cynomolgus monkey occurred after 162 days of gestation,

208 pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolg

209 dation of a humanized monoclonal antibody in cynomolgus monkeys over a time period of 12 weeks after

210 important pathogen in surgically manipulated cynomolgus monkeys, particularly with immune compromise.

211 ical' smooth muscle cells) in the murine and cynomolgus monkey pelvis-kidney junction.

212 totoxicity in vitro against Daudi cells with cynomolgus monkey peripheral blood mononuclear cells, an

213 e performed in rats (organ distribution) and cynomolgus monkeys (PET/CT imaging) to determine the GLP

214 dentified in 96 h and 168 h postdose in vivo cynomolgus monkey plasma.

215 antibody-dependent monocyte phagocytosis of cynomolgus monkey platelets, and cynomolgus platelet act

216 fusion model of thrombomodulin activation in cynomolgus monkeys, previous intravenous infusion of pha

217 isplacement experiment of [(123)I]ZIENT in a cynomolgus monkey, radioactivity was reduced by 39% in t

218 ure perfusion in one eye of 22 rhesus and 17 cynomolgus monkeys (ranging in age, respectively, from 4

219 given to rhesus macaques on days 42 and 225; cynomolgus monkeys received a booster with either PA or

220 Fourteen Cynomolgus monkeys received low dose total body irradiat

221 Eight cynomolgus monkeys received unilateral intraputamen inje

222 murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.

223 secondary lymphoid organs, and the graft in cynomolgus monkey recipients of heterotopic cardiac allo

224 Cynomolgus monkey recipients of life-supporting kidney a

225 d in a retrospective analysis on 20 selected cynomolgus monkey recipients of renal xenografts transge

226 uence of alemtuzumab (i) on ex vivo-expanded cynomolgus monkey regulatory T cells (Treg) generated fo

227 Eighty cynomolgus monkey renal allograft recipients treated wit

228 onoclonal antibodies (mAb) with sirolimus in cynomolgus monkey renal transplant recipients.

229 o by binding to endogenous PCSK9 in mice and cynomolgus monkeys, respectively.

230 rance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively.

231 al administration of R-13b to castrated male cynomolgus monkeys resulted in a significant decrease in

232 Administration of this antibody to cynomolgus monkeys resulted in B cell depletion in splee

233 rations by dietary cholesterol, seen only in cynomolgus monkeys, resulted in higher ACAT2 protein lev

234 man (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing inte

235 say was developed and qualified in human and cynomolgus monkey serum and tissues with a lower limit o

236 antibody and those derived from proteins in cynomolgus monkey serum with either d(2)- or d(0)-formal

237 uantify a recombinant monoclonal antibody in cynomolgus monkey serum.

238 and phenotypes of TALEN-edited MECP2 mutant cynomolgus monkeys serving as a model for a neurodevelop

239 In cynomolgus monkeys, SGN-CD19B effectively depleted CD20(

240 Like women, female cynomolgus monkeys show differential sensitivity to stre

241 ging with [(18)F]9-[(18)F]11 in anesthetized cynomolgus monkeys showed high uptake in the putamen wit

242 ic studies in human FcRn transgenic mice and cynomolgus monkeys showed that multiple variants with in

243 ety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally w

244 ation of 11 in conscious ocular hypertensive cynomolgus monkeys showed this compound to be efficaciou

245 Administration of bardoxolone methyl to cynomolgus monkeys significantly decreased the protein e

246 er tissues of primates, we gave adult female cynomolgus monkeys six times the human-equivalent dose o

247 However, IL-21 levels were quantified in cynomolgus monkey spleen and colon tissue and normal and

248 idly induce anovulation in a third of female cynomolgus monkeys (stress-sensitive; SS); a third will

249 pproximately 2-fold decrease in clearance in cynomolgus monkey, supporting the notion that modest inc

250 rosomal ACAT activity was 2-3-fold higher in cynomolgus monkeys than in green monkeys.

251 it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepared by c

252 ime profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough

253 , we evaluated T and B cell alloresponses in cynomolgus monkeys that had received combined kidney/bon

254 In cynomolgus monkeys, the anti-CD28 dAb demonstrated pharm

255 ed hamsters, human CETP transgenic mice, and cynomolgus monkeys, the in vivo efficacy of 12 for raisi

256 HF, we examined tissues of 21 EBOV-infected cynomolgus monkeys throughout time, and also evaluated E

257 acokinetics of two human IgG1 Fc variants in cynomolgus monkey to further clarify the affinity-pharma

258 Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-

259 Thus, expanded cynomolgus monkey Treg are resistant to alemtuzumab-medi

260 hed streptozotocin-induced diabetic juvenile cynomolgus monkeys underwent transplantation intraportal

261 ST101 were studied in 3xTg-AD mice and young cynomolgus monkeys using a combination of biochemical an

262 e the biological outcome of BAFF blockade in cynomolgus monkeys using a soluble fusion protein consis

263 swine were transplanted into the spleens of cynomolgus monkeys using conventional immunosuppression

264 development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and t

265 short tandem repeat profiling methodology to cynomolgus monkeys using two human specific alleles, TPO

266 inds with high affinity to mouse, human, and cynomolgus monkey VISTA.

267 IL-1beta from cynomolgus monkey was capable of binding and activating

268 One eye of each of 12 cynomolgus monkeys was treated with argon laser to the a

269 In a study of brainstem in the cynomolgus monkey, we found that the distribution of cal

270 In cynomolgus monkeys, we again observed a short half-life,

271 Five cynomolgus monkeys were conditioned with low-dose total

272 Adult, male cynomolgus monkeys were divided into blood-group compati

273 sign in which 31 ovariectomized adult female cynomolgus monkeys were divided into social groups of th

274 In the present study, 21 cynomolgus monkeys were experimentally infected with EBO

275 Six cynomolgus monkeys were fed a high-fat atherogenic diet

276 Cynomolgus monkeys were fed brain of (eleven) cows with

277 In a randomized crossover study, cynomolgus monkeys were fed either a control diet or a h

278 Mature (19 year old) cynomolgus monkeys were given either vehicle control (n

279 Eighteen cynomolgus monkeys were infected with MARV; blood and ti

280 To address this question, cynomolgus monkeys were injected i.v. with two doses of

281 Cynomolgus monkeys were treated topically with 150 micro

282 Eight cynomolgus monkeys were treated with intravitreal ranibi

283 Cynomolgus monkeys were used to evaluate the toxicity of

284 In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccin

285 In this study, seven cynomolgus monkeys were vaccinated with the VSVDeltaG/MA

286 cy and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution

287 nearly 4-fold increase in serum half-life in cynomolgus monkeys when compared with MEDI-524.

288 was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11beta-HS

289 age, obtained from young adult and old adult cynomolgus monkeys, which develop age-related, naturally

290 FKB8488A induced marked weight loss in obese cynomolgus monkeys while elevating serum adiponectin and

291 unodeficiency virus SHIV(89.6P) challenge of cynomolgus monkeys, while native, inactivated, or vector

292 plasma from chimpanzees; gorillas; bonobos; cynomolgus monkeys; wild-type, apoE(-/-), LDLR(-/-), and

293 MicroPET imaging in anesthetized cynomolgus monkeys with [(18)F]1-[(18)F]4 demonstrated t

294 (DKO) pig (and a GGTA1-KO pig) and immunized cynomolgus monkeys with both of these cells.

295 Weekly treatment of cynomolgus monkeys with BR3-Fc for 13 to 18 weeks result

296 hibits airway tryptase in Ascaris-sensitized cynomolgus monkeys with favorable pharmacokinetics.

297 Lastly, vaccination of cynomolgus monkeys with flagellin and a fusion of the F1

298 Interestingly, treatment of cynomolgus monkeys with JNJ-61186372 resulted in no majo

299 study evaluates the brain of a rhesus and 11 cynomolgus monkeys with Nissl staining and immunohistoch

300 Treatment of cynomolgus monkeys with SYN1436 led to a reduction of Ig